© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
NovaBridge Biosciences (NBP) stock surged +2.50%, trading at $1.64 on NASDAQ, up from the previous close of $1.60. The stock opened at $1.58, fluctuating between $1.57 and $1.65 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 26, 2026 | 1.58 | 1.65 | 1.57 | 1.64 | 171.73K |
| Jun 25, 2026 | 1.63 | 1.66 | 1.59 | 1.60 | 227.81K |
| Jun 24, 2026 | 1.61 | 1.65 | 1.59 | 1.60 | 238.17K |
| Jun 23, 2026 | 1.50 | 1.65 | 1.47 | 1.61 | 424.13K |
| Jun 22, 2026 | 1.50 | 1.55 | 1.49 | 1.53 | 262.67K |
| Jun 18, 2026 | 1.58 | 1.62 | 1.48 | 1.50 | 648.83K |
| Jun 17, 2026 | 1.54 | 1.63 | 1.49 | 1.57 | 713.97K |
| Jun 16, 2026 | 1.61 | 1.67 | 1.47 | 1.51 | 683.65K |
| Jun 15, 2026 | 1.51 | 1.55 | 1.46 | 1.47 | 567.8K |
| Jun 12, 2026 | 1.48 | 1.55 | 1.48 | 1.49 | 358.79K |
| Jun 11, 2026 | 1.53 | 1.53 | 1.46 | 1.47 | 441.27K |
| Jun 10, 2026 | 1.57 | 1.63 | 1.50 | 1.53 | 431.92K |
| Jun 09, 2026 | 1.61 | 1.64 | 1.52 | 1.59 | 402.12K |
| Jun 08, 2026 | 1.65 | 1.67 | 1.53 | 1.56 | 458.2K |
| Jun 05, 2026 | 1.78 | 1.79 | 1.62 | 1.65 | 598.51K |
| Jun 04, 2026 | 1.73 | 1.84 | 1.73 | 1.80 | 277.33K |
| Jun 03, 2026 | 1.75 | 1.77 | 1.67 | 1.75 | 562.33K |
| Jun 01, 2026 | 1.85 | 1.86 | 1.69 | 1.71 | 606.09K |
| May 29, 2026 | 1.89 | 1.91 | 1.81 | 1.84 | 361.18K |
| May 28, 2026 | 1.87 | 1.89 | 1.83 | 1.87 | 591.61K |
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
| Employees | 32 |
| Beta | 1.48 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |